Fiche publication
Date publication
juin 2025
Journal
Expert opinion on drug discovery
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Vieujean S, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
The JAK-STAT pathway plays a pivotal role in immune regulation and is implicated in the pathogenesis of Crohn's disease (CD). Upadacitinib is a JAK inhibitor with greater selectivity for JAK1 over JAK2 and JAK3, and is emerging as a promising alternative to biologic therapies in CD.
Mots clés
CELEST study, U-ENDURE, U-EXCEED, U-EXCEL, Upadacitinib, crohn’s disease
Référence
Expert Opin Drug Discov. 2025 06 27;:1-21
